A Novel Sandwich Technique of Minimally Invasive Keratoplasty for Corneal Perforation
Launched by TIANJIN EYE HOSPITAL · Jan 30, 2024
Trial Information
Current as of July 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new method called the Sandwich Technique of Minimally Invasive Keratoplasty (STMIK) to treat corneal perforations. Corneal perforations are serious conditions where a hole forms in the clear front part of the eye, which can lead to vision loss and requires immediate medical attention. The study aims to find out how effectively this new technique can help restore the eye's integrity, reduce complications, and improve vision, especially when there is not enough healthy corneal tissue available for standard repair.
To participate in this trial, individuals must have a corneal perforation that is 3mm or smaller and be willing to try this new treatment. Participants will need to provide consent and will undergo several eye tests to monitor their condition throughout the study. While this new technique shows promise, there may be some risks of complications, which the participants should discuss with their doctor. Overall, the trial is looking for ways to use existing medical materials more efficiently and improve treatment options for patients with corneal perforations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with corneal perforation who are willing to undergo treatment with this new technique;
- • 2. The size of cornea perforation was ≦ 3mm
- Exclusion Criteria:
- • 1. The size of cornea perforation was \>3mm
- • 2. Patients with corneal perforation who were unwilling to be treated with this new technique.
- • 3. Patients who could not be followed up regularly.
About Tianjin Eye Hospital
Tianjin Eye Hospital is a leading medical institution specializing in ophthalmology, dedicated to advancing eye health through innovative research and clinical excellence. As a prominent clinical trial sponsor, the hospital is committed to conducting rigorous studies that explore new treatments and therapies for a variety of eye-related conditions. With state-of-the-art facilities and a team of experienced professionals, Tianjin Eye Hospital fosters collaboration with researchers and healthcare providers to enhance patient care and contribute to the global understanding of ocular health. Its focus on patient-centered research ensures that clinical trials are designed to prioritize safety, efficacy, and the well-being of participants.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tianjin, Tianjin, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported